Viral safety remains a cornerstone of biomanufacturing, especially as biologics grow more complex and development timelines accelerate. Manufacturers face mounting pressure to ensure products are safe and compliant, while keeping production efficient and meeting rigorous regulatory standards.

SGS addresses this challenge with its CHO uBH accelerated viral safety testing approach. Leveraging GMP-compliant TaqMan PCR technology, the method rapidly detects over 39 viral targets across more than 15 high-risk virus families. By significantly shortening testing timelines, SGS helps biomanufacturers streamline downstream processing while ensuring robust biosafety and regulatory compliance.

The strength of the company’s approach lies in its depth of virology expertise and proven regulatory alignment. With more than 25 years of experience in biosafety testing, SGS delivers validated methods designed to meet ICH Q2 (R2) requirements. Cell bank characterisation packages are aligned with ICH Q5A (R2), Q5B and Q5D, supporting manufacturers from early development through to commercial release.

SGS operates a Glasgow-based centre of excellence that supports a wide range of advanced modalities, including gene and cell therapies, viral vaccines, recombinant proteins, monoclonal antibodies and mRNA therapeutics. This breadth of capability allows SGS to support complex biologics programmes with confidence and consistency.

Reliability is central to the service. SGS maintains an on-time delivery rate exceeding 95 per cent, helping clients reduce risk and keep development programmes on track. From early-stage research and cell bank characterisation to GMP manufacturing, routine QC testing and commercial licensing, SGS provides continuity across the product lifecycle.

What sets SGS apart is its collaborative model. Expert teams work closely with clients to design tailored testing strategies that reflect specific regulatory requirements and project timelines. This partnership approach ensures faster decision-making and greater clarity throughout development.

By combining accelerated testing, scientific depth and regulatory expertise, SGS enables biomanufacturers to de-risk development pathways and bring high-quality biopharmaceutical products to market with confidence.

Download the SGS Viral Safety Testing brochure to learn more about the CHO uBH accelerated testing approach and biosafety solutions here.